SLB a rising biotechology stock LONGSLN has appreciated 70% in the past month largly on the strength of an
earnings beat. Unlike many small cap biotechnology companies, SLN is
actually making money and beating analyst's estimates. On the 3O minute
chart, price is just below the POC line of the near term volume profile and
sitting
